A case of Raynaud's phenomenon in mixed connective tissue disease responding to rituximab therapy [4]

Rheumatology

Volumn 46, Issue 4, 2007, Pages 718-719

  Haroon, M ^a   O'Gradaigh, Donncha ^a   Foley Nolan, D ^a  

^a WATERFORD REGIONAL HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; ILOPROST; METHYLPREDNISOLONE; PREDNISOLONE; RIBONUCLEOPROTEIN ANTIBODY; RITUXIMAB; TADALAFIL;

ADULT; ANALGESIA; CASE REPORT; CLINICAL PROTOCOL; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG DOSE TITRATION; FEMALE; HUMAN; LETTER; MIXED CONNECTIVE TISSUE DISEASE; PRIORITY JOURNAL; RAYNAUD PHENOMENON; RELAPSE; SYMPTOM; ULCER HEALING;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; MIXED CONNECTIVE TISSUE DISEASE; RAYNAUD DISEASE;

EID: 34047187057     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem003     Document Type: Letter

References (10)

1. Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated for B lymphocyte depletion. Ann Rheum Dis 2002;61:883-8.
2. Edwards JCW, Szczepanski L, Szechinski J et al. Efficacy and safety of rituximab, a B-cell targeted chimeric monoclonal antibody: A randomised placebo controlled trial in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2002;(suppl 9):S446.
3. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002;46:2673-7.
4. Edwards JCW, Szczepanski L, Szechinski J et al. Efficacy of B-cell targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.
5. Gottenberg J-E, Guillevin L, Lambotte O et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005;64:913-20.
6. Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA. B-cell depletion in the treatment of pateints with systemic lupus erythematosus: A longitudinal analysis of 24 patients. Rheumatology 2005;44:1542-5.
7. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I. B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004;50:2580-9.
8. Cambridge G, Leandro MJ, Edwards JCW, Ehrenstein MR, Salden M, Webster D. B-lymphocyte depletion in patients with rheumatoid arthritis: Serial studies of immunological parameters [abstract]. Arthritis Rheum 2002;(suppl 9):S1350.
9. Senécal JL, Hénault J, Raymond Y. The pathogenic role of autoantibodies to nuclear autoantigens in systemic sclerosis (scleroderma). J Rheum 2005;32:1643-9.
10. Weide R, Heymanns J, Pandorf A, Koppler H. Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy. Lupus 2003;12:779-82